Kyverna Therapeutics Inc. (KYTX)
NASDAQ: KYTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
KYTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $269.33M
- EPS (TTM)
- -$2.75
- Dividend yield
- None
- 52-week range
- 4.18 – 13.67
- Day range
- 4.18 – 4.58
- Volume / Avg
- 1.34M / 867.28K
- Beta
- —
- Shares outstanding
- 63.22M
52-week range
KYTX stock today
Shares of Kyverna Therapeutics (KYTX) finished lower on Nov 20 at $4.26, a drop of 2.52% or $0.11 per share, versus the S&P 500's 3.70% decline. At this level, KYTX sits near the bottom of its 52-week range of $4.18 to $13.67: 68.8% below the high, set on Dec 15, 2025 and 2.0% above the low. KYTX is down 54.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 39.9%.
Kyverna Therapeutics has posted a net loss over the last twelve months (EPS of -$2.75), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Kyverna Therapeutics
Company profileKyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Warner Biddle
- Headquarters
- Emeryville, CA
- Employees
- 172
- IPO year
- 2024
- Website
- kyvernatx.com
Financial highlights
Full financialsKyverna Therapeutics reported a net loss of $161.3 million, compared with a loss of $127.5 million a year earlier. Diluted earnings per share came in at -$3.64.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | — | — | — |
| Growth | — | — | — |
| Net income | $-161.31M | $-127.48M | $-60.37M |
| EPS (diluted) | $-3.64 | $-3.33 | $-89.61 |
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$30.40+613.62%
- Strong buy 2
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.68 vs $-0.68
- Surprise
- 0.00%
KYTX news
All KYTX news- Kyverna Therapeutics, Inc. Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial ResultsNasdaqKYTX, WSO.B
- Kyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- Kyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA NeurologyGlobeNewswire
- Kyverna Therapeutics to Present at the Jefferies London Healthcare ConferenceGlobeNewswire
- Oversold Conditions For Kyverna Therapeutics (KYTX)NasdaqKYTX, ET
- Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026GlobeNewswire
- Kyverna's Miv-cel Shows 49% Walking Improvement At One Year; Stock DownNasdaqKYTX, SUN
- Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS TorontoGlobeNewswire
Kyverna Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AGENAgenus Inc. | 5.97 | -2.77% | $270.12M | vs KYTX |
| AGMBAgomAb Therapeutics NV ADR | 5.45 | -3.02% | $268.40M | vs KYTX |
| OCGNOcugen Inc. | 0.7679 | +4.79% | $260.55M | vs KYTX |
| EIKNEikon Therapeutics Inc. | 4.74 | -0.42% | $256.84M | vs KYTX |
| DTILPrecision BioSciences Inc. | 7.40 | +7.09% | $282.46M | vs KYTX |
| SABSSAB Biotherapeutics Inc. | 2.81 | -3.44% | $253.15M | vs KYTX |
| EDITEditas Medicine Inc. | 1.64 | -4.09% | $253.12M | vs KYTX |
| LXEOLexeo Therapeutics Inc. | 2.96 | +0.34% | $245.05M | vs KYTX |
Indexes, lists and sector
Kyverna Therapeutics stock FAQ
What is Kyverna Therapeutics's stock price today?
KYTX last traded at $4.26 as of Nov 20, 4:00 PM EST, down 2.52% on the day. Prices are delayed at least 15 minutes.
Who is Kyverna Therapeutics's CEO?
Mr. Warner Biddle is the chief executive officer of Kyverna Therapeutics Inc., which has about 172 employees.
What is the KYTX 52-week high?
The 52-week high for KYTX is $13.67 and the 52-week low is $4.18. The stock is currently 68.8% below its high.